{"id":784530,"date":"2023-09-18T09:28:28","date_gmt":"2023-09-18T13:28:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\/"},"modified":"2023-09-18T09:28:28","modified_gmt":"2023-09-18T13:28:28","slug":"evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\/","title":{"rendered":"Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"text-align:justify\">AI-powered target discovery for a bacterial pathogen with a high medical need where no vaccine is currently available\u00a0<\/li>\n<li style=\"text-align:justify\">Evaxion\u2019s proprietary AI-platforms EDEN\u2122\u00a0and RAVEN\u2122 will be utilized for rapid design of a completely novel vaccine candidate capable of eliciting both a humoral (antibody) and cellular immune response to the pathogen<\/li>\n<li style=\"text-align:justify\">Collaborative and co-funded project between two companies with strong scientific alignment and complementary skill sets and capabilities<\/li>\n<li style=\"text-align:justify\">This collaboration underlines Evaxion\u2019s strategic focus of harnessing the power of AI to identify new targets significantly more efficiently than traditional methods<\/li>\n<\/ul>\n<p align=\"justify\">COPENHAGEN, Denmark, Sept.  18, 2023  (GLOBE NEWSWIRE) &#8212; Evaxion Biotech A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced the initiation of a novel pipeline program, EVX-B3, an AI-designed vaccine candidate against an undisclosed bacterial pathogen. The new vaccine project will be a collaboration between Evaxion and an undisclosed leading pharmaceutical company, leveraging unique assets and know-how from both organizations.<\/p>\n<p align=\"justify\">To develop an effective vaccine, Evaxion has initiated discovery activities for EVX-B3 using both its EDEN\u2122 and RAVEN\u2122 AI platforms to identify protective antigens capable of eliciting both a humoral (antibody) and cellular response to the pathogen. EVX-B3 aims to address a serious global medical issue, targeting a pathogen associated with repeated infections, increasing incidence and often serious medical complications, and for which no vaccines are currently available. The project will be a collaborative and co-funded effort between the two companies.<\/p>\n<p align=\"justify\">Evaxion\u2019s Chief Scientific Officer, Birgitte R\u00f8n\u00f8, states: \u201cWe are thrilled to announce our upcoming collaboration, aimed at jointly investigating the capabilities of our AI platforms to design a groundbreaking vaccine targeting this specific pathogen. We strongly believe that this collaboration will further validate the power of AI to benefit global health through the design of unique vaccines against serious medical conditions.\u201d<\/p>\n<p>\n        <strong>About<\/strong><br \/>\n        <strong>EDEN<\/strong><br \/>\n        <strong>\u2122<\/strong>\u00a0<\/p>\n<p align=\"justify\">EDEN\u2122 is a proprietary AI platform capable of rapidly identifying those antigens that will trigger a robust and highly protective immune response against virtually any bacterial infectious disease. EDEN\u2122 is fully AI-driven and designed to identify vaccine candidates faster and cheaper than current state-of-the-art methods. With EDEN\u2122, we take a novel approach to vaccine development to combat the rising global issue of antibiotic resistance. For more information, visit our <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2RqHtL6O3wSUhoLlZPZdOfR1WkYlDw3wyLDlgSWK5sVLau9ctaJ3E5ARHGVlvA6zHtcDVJRee1VrPKh0VJCsBGAG7P_4t9Hgk1dXZc3jheB2ieKlGM0jO0X3UGARTRp-\" rel=\"nofollow noopener\" target=\"_blank\"><u>website<\/u><\/a>.\u00a0<\/p>\n<p>\n        <strong>About<\/strong><br \/>\n        <strong>RAVEN\u2122<\/strong>\u00a0<\/p>\n<p align=\"justify\">RAVEN\u2122 is a proprietary AI platform that rapidly identifies vaccine candidates against existing, emerging, and mutating viral diseases. We are developing next-generation vaccine candidates that aim to simultaneously trigger potent B- and T-cell responses. Current vaccines against viral infection are challenged by fading efficacy and evasion by mutating viruses. With RAVEN\u2122, the addition of the T-cell component is designed to secure broader, more durable protection. For more information, visit our <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2RqHtL6O3wSUhoLlZPZdOe6T6oYvun3PtkTr4iX3rqoD8poaGZ6VXgH6aJ0XJ9zZ32FlDDxytBnmBmaJSmH2Yx4OUnLeoPva6KON8Ibz33Z5jz77pZPPSLFdjfsNal92\" rel=\"nofollow noopener\" target=\"_blank\"><u>website<\/u><\/a>.\u00a0<\/p>\n<p align=\"justify\">\n        <strong>About EVAXION<\/strong>\u00a0<br \/>Evaxion Biotech A\/S is a clinical-stage biotech company developing world-leading AI platforms. Evaxion&#8217;s proprietary and scalable technologies harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. The company is committed to transforming patients&#8217; lives with unmet clinical needs by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking immunotherapies, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vTJSu0xTnPyR8R96ZCpbdP6uZC_CLMPJ5HtImygXV35LE73oA14GufRxTybw07_5tikG2W1Weiy1OeTjDBVOElJ5hEc5z7wdcjfK6ns6YRY=\" rel=\"nofollow noopener\" target=\"_blank\">www.evaxion-biotech.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-looking statement<\/strong>\u00a0<br \/>This\u00a0announcement contains forward-looking statements\u00a0within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.\u00a0The words\u00a0\u201ctarget,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201chope,\u201d \u201caim,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201canticipate,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cwill,\u201d \u201ccan have,\u201d \u201clikely,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccould,\u201d and other words and terms of similar meaning\u00a0identify forward-looking statements.\u00a0Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares,\u00a0the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our\u00a0business from the worldwide COVID-19 pandemic and the ongoing conflict in the region surrounding\u00a0Ukraine\u00a0and\u00a0Russia;\u00a0and other uncertainties affecting our business operations and financial condition.\u00a0For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F\u00a0and other filings\u00a0with the U.S. Securities and Exchange Commission (SEC), which are available at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vTJSu0xTnPyR8R96ZCpbdGVhBEKcuNt0PCpsbF8Mvo2YBE48YWzE-YDSizCT7fJ0aVnAujO5BxK3vAVsus8WAg==\" rel=\"nofollow noopener\" target=\"_blank\"><strong><u>www.sec.gov<\/u><\/strong><\/a>.\u00a0We do not assume any obligation to update any forward-looking statements except as required by law.\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzOTk0MCM0MDE2MTA0MDkjMjI1MjA4Nw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/MWM0NmY1ZWQtYzEzNS00MjU2LWE4NTMtMWFmN2MwMjdlMzQ3LTEyNjM2NDA=\/tiny\/Evaxion-Biotech.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Contact information\u00a0\r\nEvaxion Biotech A\/S\r\nChristian Kanstrup\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\r\nChief Executive Officer\r\ncka@evaxion-biotech.com\r\nSource: Evaxion Biotech<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AI-powered target discovery for a bacterial pathogen with a high medical need where no vaccine is currently available\u00a0 Evaxion\u2019s proprietary AI-platforms EDEN\u2122\u00a0and RAVEN\u2122 will be utilized for rapid design of a completely novel vaccine candidate capable of eliciting both a humoral (antibody) and cellular immune response to the pathogen Collaborative and co-funded project between two companies with strong scientific alignment and complementary skill sets and capabilities This collaboration underlines Evaxion\u2019s strategic focus of harnessing the power of AI to identify new targets significantly more efficiently than traditional methods COPENHAGEN, Denmark, Sept. 18, 2023 (GLOBE NEWSWIRE) &#8212; Evaxion Biotech A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced the initiation &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-784530","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AI-powered target discovery for a bacterial pathogen with a high medical need where no vaccine is currently available\u00a0 Evaxion\u2019s proprietary AI-platforms EDEN\u2122\u00a0and RAVEN\u2122 will be utilized for rapid design of a completely novel vaccine candidate capable of eliciting both a humoral (antibody) and cellular immune response to the pathogen Collaborative and co-funded project between two companies with strong scientific alignment and complementary skill sets and capabilities This collaboration underlines Evaxion\u2019s strategic focus of harnessing the power of AI to identify new targets significantly more efficiently than traditional methods COPENHAGEN, Denmark, Sept. 18, 2023 (GLOBE NEWSWIRE) &#8212; Evaxion Biotech A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced the initiation &hellip; Continue reading &quot;Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-18T13:28:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzOTk0MCM0MDE2MTA0MDkjMjI1MjA4Nw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company\",\"datePublished\":\"2023-09-18T13:28:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\\\/\"},\"wordCount\":820,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgzOTk0MCM0MDE2MTA0MDkjMjI1MjA4Nw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\\\/\",\"name\":\"Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgzOTk0MCM0MDE2MTA0MDkjMjI1MjA4Nw==\",\"datePublished\":\"2023-09-18T13:28:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgzOTk0MCM0MDE2MTA0MDkjMjI1MjA4Nw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgzOTk0MCM0MDE2MTA0MDkjMjI1MjA4Nw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\/","og_locale":"en_US","og_type":"article","og_title":"Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company - Market Newsdesk","og_description":"AI-powered target discovery for a bacterial pathogen with a high medical need where no vaccine is currently available\u00a0 Evaxion\u2019s proprietary AI-platforms EDEN\u2122\u00a0and RAVEN\u2122 will be utilized for rapid design of a completely novel vaccine candidate capable of eliciting both a humoral (antibody) and cellular immune response to the pathogen Collaborative and co-funded project between two companies with strong scientific alignment and complementary skill sets and capabilities This collaboration underlines Evaxion\u2019s strategic focus of harnessing the power of AI to identify new targets significantly more efficiently than traditional methods COPENHAGEN, Denmark, Sept. 18, 2023 (GLOBE NEWSWIRE) &#8212; Evaxion Biotech A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced the initiation &hellip; Continue reading \"Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-18T13:28:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzOTk0MCM0MDE2MTA0MDkjMjI1MjA4Nw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company","datePublished":"2023-09-18T13:28:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\/"},"wordCount":820,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzOTk0MCM0MDE2MTA0MDkjMjI1MjA4Nw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\/","name":"Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzOTk0MCM0MDE2MTA0MDkjMjI1MjA4Nw==","datePublished":"2023-09-18T13:28:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzOTk0MCM0MDE2MTA0MDkjMjI1MjA4Nw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzOTk0MCM0MDE2MTA0MDkjMjI1MjA4Nw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/784530","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=784530"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/784530\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=784530"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=784530"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=784530"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}